Showing 6081-6090 of 9451 results for "".
Dermwire TV: Topical Caffeine for Hair Growth, Tapinarof for Pediatric AD
https://practicaldermatology.com/videos/dermwire-tv/dermwire-tv-topical-caffeine-for-hair-growth-tapinarof-for-pediatric-ad/48734/This episode highlights studies showing potential for topical caffeine in hair growth in patients with alopecia areata, as well as recent positive results for tapinarof cream 1% for children with AD. Also, Cutera CEO Taylor Harris talks with Practical Dermatology about the evolving needs of today’sPractical Strategies for Improving Patient Adherence with Topical Regimens
https://practicaldermatology.com/videos/dermatology-hub-neuroimmune-network/practical-strategies-for-improving-patient-adherence-with-topical-regimens/39707/Justin Marson, MD, Chief Resident 2024-25 in the Department of Dermatology at SUNY Downstate Health Science University, describes tactics involving topical therapeutics to improve patient adherence with atopic dermatitis.Increased APS Risk for Psoriasis Patients, Plus More
https://practicaldermatology.com/videos/dermwire-tv/increased-aps-risk-for-psoriasis-patients-plus-more/39299/This episode highlights research showing increased risk for anti-phospholipid syndrome (APS) in patients with psoriatic disease, as well as research showing increased risks for tuberculosis in patients treated with immunosuppressants. The episode also features a clip from an in-depth discussion arouWhen and How to Use Ancillary Testing
https://practicaldermatology.com/programs/practical-dermatology-updates-in-skin-cancer/when-and-how-to-use-ancillary-testing/35598/Hadas Skupsky, MD, a board-certified dermatologist and dermatopathologist, discusses when a dermatopathologist decides to use ancillary testing for melanoma, how that impacts final diagnosis, and how it can guide treatment decisions.The Dermatology & Aesthetics Mergers and Acquisitions Market
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/the-dermatology-aesthetics-mergers-and-acquisitions-market/33166/Over the past decade, the dermatology and aesthetics mergers and acquisitions (M&A) market has experienced notable trends that continue to shape its trajectory.Breakthroughs in Alopecia Areata Treatment
https://practicaldermatology.com/conferences/masterclasses-in-dermatology-2025/breakthroughs-in-alopecia-areata-treatment/33019/Adelaide A. Hebert, MD, chief of pediatric dermatology at the University of Texas Medical School in Houston, talks about her presentation at Masterclasses in Dermatology 2025 discusses breatkthrough treatments for alopecia areata in patients aged 12 and older.A Key to Successful Teen Acne Treatment
https://practicaldermatology.com/topics/acne-rosacea/Key-Successful-Teen-Acne-Treatment/32981/Acne has a significant psychological aspect that affects the quality of life of adolescents. The appearance of acne often causes feelings of shame, reduced self-esteem, anxiety, and even depression in young people. In some cases, it can lead to difficulties in social adaptation and social isolation,Acne and Rosacea: Dr. Harper
https://practicaldermatology.com/programs/practical-dermatology/acne-and-rosacea-dr-harper/32686/Julie Harper, MD, summarizes her presentation during the "Update 2025: Acne and Rosacea" session at Maui Derm 2025, which focused on spironolactone, oral contraceptives, and topical clascoterone.Vtama Approved for AD in Adults and Children
https://practicaldermatology.com/videos/dermwire-tv/vtama-approved-ad-adults-and-children/30079/In this week's DermwireTV, the FDA approves Vtama (tapinarof cream 0.1%) for atopic dermatitis in adults and children; the FDA approves Nemluvio (nemolizumab) for moderate-to-severe AD; and the president of Nuance Medical discusses the acquisition of scar treatment brand, Biocorneum.Experts React to Latest Benzene Analysis
https://practicaldermatology.com/videos/dermwire-tv/experts-react-to-latest-benzene-analysis/29810/In this week's DermwireTV, Practical Dermatology Editorial Board members provide their thoughts on the recent analysis examining benzene concentrations in BPO products; Johnson & Johnson seeks new indications for IL-23 inhibitor Tremfya; and the founder and CEO of Terns discusses plans to improv